Associate Professor of Internal Medicine
[email protected]
Available to mentor
Geoffrey D Barnes, MD, MSc
Associate Professor
Dr. Barnes is a cardiologist and vascular medicine specialist. His research focuses on developing, implementing, and evaluating antithrombotic stewardship efforts to improve the care of patients with thrombotic conditions and/or those who use anticoagulant medications. He serves as co-director for the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) and as co-director for the Michigan Program on Value Enhancement (MPrOVE). His research is funded by the NIH, AHRQ, and Blue Cross-Blue Shield of Michigan. He serves in leadership roles with several national and International organizations, including the Anticoagulation Forum, American College of Cardiology, and International Society on Thrombosis and Hemostasis. He also serves as the program director for the University of Michigan Vascular Medicine fellowship training program.
-
Cardiovascular Medicine FellowshipUniversity of Michigan, Internal Medicine/Cardiovascular Medicine, 2014
-
Vascular Medicine FellowshipUniversity of Michigan, Internal Medicine/Cardiovascular Medicine, 2014
-
Internal Medicine Chief ResidencyUniversity of Michigan, Internal Medicine, 2011
-
Internal Medicine ResidencyUniversity of Michigan, Internal Medicine, 2010
-
MSUniversity of Michigan, Ann Arbor, 2015
-
MDUniversity of Michigan, 1500 E. Medical Center Drive, 2007
-
BSWashington University in St. Louis, St. Louis, 2003
-
Center MemberPrecision Health Initiative
-
Center MemberCenter for Bioethics and Social Sciences in Medicine
-
Center MemberInstitute for Healthcare Policy and Innovation
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
Anticoagulation therapy
Venous Thromboembolism
Implementation Science
Quality Improvement
Health systems engineering
Shared decision-making
-
Nayak T, Christensen JT, Bardsley T, Barnes GD, Cameron KA, Passman R, Kansal P, Witt DM, Cavanaugh KL, Fagerlin A, Ozanne EM, STEP-UP AF Writing Group . Contemp Clin Trials, 2024 Dec 5; 148: 107773Journal ArticleEvaluation of patient and encounter decision aid interventions for atrial fibrillation: Baseline characteristics of the RED-AF study - A Randomized Controlled Trial.
DOI:10.1016/j.cct.2024.107773 PMID: 39645031 -
Benavente K, Fujiuchi B, Virk HUH, Kavali PK, Ageno W, Barnes GD, Righini M, Alam M, Rosovsky RP, Krittanawong C. Journal of Clinical Medicine, 13 (24): 7637 - 7637.Journal ArticleA Practical Clinical Approach to Navigate Pulmonary Embolism Management: A Primer and Narrative Review of the Evolving Landscape
DOI:10.3390/jcm13247637 -
Han H, O'Hare C, Joyce E, Kline JA, Greineder CF, Barnes GD. J Thromb Haemost, 2024 Dec; 22 (12): 3406 - 3414.Journal ArticleJTH in Clinic: management of low-risk pulmonary embolism.
DOI:10.1016/j.jtha.2024.09.019 PMID: 39395541 -
Barnes GD, Gorog DA. J Thromb Thrombolysis, 2024 Dec; 57 (8): 1281 - 1282.Journal ArticleNovel antithrombotic approaches in cardiovascular disease - what is on the horizon?
DOI:10.1007/s11239-024-03062-2 PMID: 39602065 -
Bank M, Krischak M, Skolarus T, Lewicki P, Sekar R, Herrel L, Barnes GD, Ghani K, Piatt G, Vince R, Stensland K. Urol Oncol, 2024 Dec; 42 (12): 452.e15 - 452.e19.Journal ArticlePrevalence of unnecessary kidney function exclusion criteria in urologic oncology clinical trials.
DOI:10.1016/j.urolonc.2024.08.017 PMID: 39393993 -
Barnes GD, Lip GYH. J Am Coll Cardiol, 2024 Nov 19; 84 (21): 2154 - 2156.Journal ArticleApplying Clinical Risk Scores in Real-World Practice: The CHA2DS2-VASc Score in Atrial Fibrillation.
DOI:10.1016/j.jacc.2024.08.017 PMID: 39365222 -
Burke KS, Kong X, Haymart B, DeCamillo D, Ali M, Barnes G, Kaatz S. Research and Practice in Thrombosis and Haemostasis, 2024 Nov 1; 8 (8):Journal ArticleComparing rates of clinically relevant epistaxis in patients taking warfarin versus direct oral anticoagulants
DOI:10.1016/j.rpth.2024.102630 -
Ardeshna N, Feldeisen T, Kong X, Haymart B, Kaatz S, Ali M, Barnes GD, Froehlich JB. Vasc Med, 2024 Oct; 29 (5): 543 - 552.Journal ArticleComparing DOAC and warfarin outcomes in an obese population using the 'real-world' Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry.
DOI:10.1177/1358863X241264478 PMID: 39177515
Health Lab
For people taking the popular blood thinners rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis), after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests.
Health Lab
Doctors and pharmacists treating people with blood thinners can now reduce the rate of inappropriate dosing — as well as blood clots and strokes that can result from it — using an electronic patient management system.
Health Lab
More than two-thirds of those people take a type of blood thinner called a direct oral anticoagulant. These DOACs, such as rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis), are under- or over-prescribed in up to one in eight patents. These prescribing issues can have life-threatening consequences, and they most often occur after a provider writes the initial prescription, according to a study led by Michigan Medicine.
Research News
Dr. Geoff Barne's named on the 2024 Top LGBTQ+ Doctors List
